Drug Target Review
AUGUST 28, 2024
We then incubate the cells to mature into ‘pro-regenerative’ macrophages and insert two RNA messages to produce two human proteins that will be expressed at the site of injury when these ‘engineered’ macrophages are given back to the patient. The patient’s own monocytes, a type of white blood cell, are removed via an apheresis procedure.
The Pharma Data
MARCH 8, 2021
Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Strateos Blog: Drug Discovery
DECEMBER 13, 2021
Learn how Strateos’ automated synthetic biology modules supported rapid, iterative screening of RNA sequences in modular pbuE expression system and E. Owing to their modular organization, riboswitches are ideal for engineering de novo sensing elements for use in synthetic biology. coli extract-based cell-free protein expression assays.
The Pharma Data
OCTOBER 25, 2021
At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? Merck Research Laboratories. “ 50 clones/ mL, demonstrating that antiviral efficacity was similar between DOR/ ISL and ART ( ILLUMINATE SWITCH A) and between DOR/ ISL and BIC/ FTC/ TAF (ILLUMINATE SWITCH B).
The Pharma Data
JULY 12, 2021
“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir.
The Pharma Data
NOVEMBER 18, 2021
As previously reported, at 48 weeks, both trials met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels ?50 All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”.
The Pharma Data
SEPTEMBER 1, 2021
Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir.
Expert insights. Personalized for you.
116 
Let's personalize your content